IDDI, Biostatistical and eClinical Services for Clinical Trials

TRIAL DESIGN - RANDOMIZATION - DATA MANAGEMENT - BIOSTATISTICS
Twitter icon
Facebook icon
LinkedIn icon
Google+ icon
YouTube icon
RSS icon

Secondary menu

Home > Therapeutic expertise

Therapeutic expertise

IDDI has been involved in over 900 clinical trials since its inception.

The company’s core area of therapeutics expertise is in cancer research with substantial experience in ophthalmologycardiovascular and CNS diseases.

Over the last five years, IDDI has conducted 336 phase I-IV clinical trials.  

 

IDDI’s broad range of expertise is reflected in its expert publications throughout various medical and statistical journals (available on request) and through its presence at major meetings and congresses (list provided on request).

 

  • Experience in the Main Therapeutic Areas 

Therapeutic areas

Experience over the last 5 years
 (# of trials)

Global Experience
(# of trials)

ONCOLOGY

224 cancer trials

 

586 trials

 

 

The company has been involved in 12 market approvals of anti-cancer therapies.
 

OPHTHALMOLOGY

28 ophthalmic trials

 

99 trials

 

 

IDDI’s contributed methodology and integrated technology supported Macugen® market approval.

 

CARDIOLOGY 

11 cardiology trials
 

48 trials
 

CNS (Central Nervous System)

 

15 CNS trials  31 trials 
Musculoskeletal (Connective Tissue)  17 trials

27 trials 

 

BIOSIMILARS

Currently involved in 10 clinical trials, primarily related to the second generation of monoclonal antibodies.

 

Orphan Drugs  IDDI has worked on 38 orphan drug studies 

 

  • OTHER SIGNIFICANT AREAS

    • Infectious disease, central nervous system, autoimmune diseases, nutrition.
    • Biosimilars.
    • Medical Devices:
      • Our processes conform to medical device studies, both for pilot and pivotal studies.
      • We help our clients achieve the CE marking and FDA approvals for medical devices.
      • IDDI has successfully helped a cardio-vascular device approved in the US, and the validation of a cancer diagnosis also submitted to the FDA.

 

EXPERIENCE in clinical trials (% OF TRIALS OVER THE LAST 5 YEARS)